Cyclic Nucleotide Phosphodiesterases: important signaling modulators and therapeutic targets
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
By catalyzing hydrolysis of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), cyclic nucleotide phosphodiesterases are critical regulators of their intracellular concentrations and their biological effects. As these intracellular second messengers control many cellular homeostatic processes, dysregulation of their signals and signaling pathways initiate or modulate pathophysiological pathways related to various disease states, including erectile dysfunction, pulmonary hypertension, acute refractory cardiac failure, intermittent claudication, chronic obstructive pulmonary disease, and psoriasis. Alterations in expression of PDEs and PDE‐gene mutations (especially mutations in PDE6, PDE8B, PDE11A, and PDE4) have been implicated in various diseases and cancer pathologies. PDEs also play important role in formation and function of multimolecular signaling/regulatory complexes, called signalosomes. At specific intracellular locations, individual PDEs, together with pathway‐specific signaling molecules, regulators, and effectors, are incorporated into specific signalosomes, where they facilitate and regulate compartmentalization of cyclic nucleotide signaling pathways and specific cellular functions. Currently, only a limited number of PDE inhibitors (PDE3, PDE4, PDE5 inhibitors) are used in clinical practice. Future paths to novel drug discovery include the crystal structure‐based design approach, which has resulted in generation of more effective family‐selective inhibitors, as well as burgeoning development of strategies to alter compartmentalized cyclic nucleotide signaling pathways by selectively targeting individual PDEs and their signalosome partners.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osteoclast differentiation and activation
Boyle, W. J., Simonet, W. S., & Lacey, D. L. (2003) · Nature · doi:10.1038/nature01658 · Cited by 6,670 · cited 1×
“Maintenance of normal bone mass depends on the balance between osteoblast bone formation and osteoclast bone destruction (Duong and Rodan, 2001; Boyle et al, 2003).”
BackgroundBehavioral phenotypes of Disc1 missense mutations in mice
Clapcote, S. J., Lipina, T. V., Millar, J. K., Mackie, S., Christie, S., Ogawa, F., Lerch, J. P., Trimble, K., Uchiyama, M., Sakuraba, Y., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.04.015 · Cited by 526
Glucocorticoid-Induced Osteoporosis
Buckley, L., & Humphrey, M. B. (2018) · New England Journal of Medicine · doi:10.1056/nejmcp1800214 · Cited by 438
Robichaud, A., Stamatiou, P. B., Jin, S.-L. C., Lachance, N., MacDonald, D., Laliberté, F., Liu, S., Huang, Z., Conti, M., & Chan, C.-C. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15506 · Cited by 267 · cited 4×
“Multiple studies, especially those with PDE4 KO mice, have pointed to inhibition of PDE4D and not other PDE4 isoforms as most likely responsible for the emetic effects (Robichaud et al, 2002) as well as the antidepressant and pro-cognitive and memory-enhancing responses to pan-PDE4 inhibitors.”
BackgroundInfluentialYuan, J., Zhang, R., Yang, Z., Lee, J., Liu, Y., Tian, J., Qin, X., Ren, Z., Ding, H., Chen, Q., et al. (2013) · European Urology · doi:10.1016/j.eururo.2013.01.012 · Cited by 260
Phototransduction: crystal clear
Ridge, K. D., Abdulaev, N. G., Sousa, M., & Palczewski, K. (2003) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(03)00172-5 · Cited by 163 · cited 1×
“PDE6 is highly expressed in photoreceptors and pineal gland (Morin et al, 2001; Ridge et al, 2003).”
BackgroundEHT0202 in Alzheimers Disease: A 3-Month, Randomized, Placebo- Controlled, Double-Blind Study
Vellas, B., Sol, O., J. Snyder, P., Ousset, P.-J., Haddad, R., Maurin, M., Lemarie, J.-C., Desire, L., & P. Pando, M. (2011) · Current Alzheimer Research · doi:10.2174/156720511795256053 · Cited by 133
Rothenbuhler, A., Horvath, A., Libé, R., Faucz, F. R., Fratticci, A., Raffin Sanson, M. L., Vezzosi, D., Azevedo, M., Levy, I., Almeida, M. Q., et al. (2012) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2012.04366.x · Cited by 96 · cited 1×
“Mutations in human PDE8B, however, are associated with development of micronodular adrenal hyperplasia, adrenocortical tumors, and clinical signs of Cushing disease (Rothenbuhler et al, 2012).”
BackgroundUpdate in new anabolic therapies for osteoporosis
Canalis, E. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2677 · Cited by 85 · cited 1×
“Currently, Forteo (N-terminal PTH peptide, 1-34 amino acid) is FDA-approved for anabolic treatment of osteoporosis (Hodsman et al, 2005; Canalis, 2010).”
BackgroundMacKenzie, K. F., Wallace, D. A., Hill, E. V., Anthony, D. F., Henderson, D. J. P., Houslay, D. M., Arthur, J. S. C., Baillie, G. S., & Houslay, M. D. (2011) · Biochemical Journal · doi:10.1042/bj20101184 · Cited by 65 · cited 1×
“…2011) PDE4 Disc1 PDE4D9, ATF4, D1-R Neuronal functions (Soda et al, 2013) Disc1 PDE4A5, MK2, PKA and AIP Immune, inflammatory, and stress responses (MacKenzie et al, 2011) Disc1 PDE4B, GSK3 Etiology of schizophrenia and depression (Lipina et al, 2012) AKAP18d PKA,PDE4D Water reabsorption (Stefan…”
Background
Cited by
Therapeutic targeting of 3′,5′-cyclic nucleotide phosphodiesterases: inhibition and beyond
Baillie, G. S., Tejeda, G. S., & Kelly, M. P. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0033-4 · Cited by 339
Targeting cell signaling in allergic asthma
Athari, S. S. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0079-0 · Cited by 312
Nitric oxide/cGMP/CREB pathway and amyloid-beta crosstalk: From physiology to Alzheimer’s disease
Tropea, M. R., Gulisano, W., Vacanti, V., Arancio, O., Puzzo, D., & Palmeri, A. (2022) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.11.022 · Cited by 55
Metadata
- Authors
- Ahmad, F., Murata, T., Shimizu, K., Degerman, E., Maurice, D., & Manganiello, V
- Venue
- Oral Diseases
- Publisher
- Wiley
- Published
- 2014-09-12
- Volume
- 21
- Issue
- 1
- Pages
- e25-50
- ISSN
- 1354-523X (ISSN-L)
- 1601-0825
- OpenAlex
- W2049374415
- Cited by
- 184
- References
- 10
- FWCI
- 3.16
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cyclic Nucleotide Phosphodiesterases: important signaling modulators and therapeutic targets. https://app.cochat.ai/papers/10.1111/odi.12275
- The paper
- Ahmad, F., Murata, T., Shimizu, K., Degerman, E., Maurice, D., & Manganiello, V. (2015). Cyclic Nucleotide Phosphodiesterases: important signaling modulators and therapeutic targets. Oral Diseases. https://doi.org/10.1111/odi.12275
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.